ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) has been given a consensus broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and two have issued a strong buy rating on the company.
Analysts have set a 1 year consensus target price of $5.10 for the company, according to Zacks. Zacks has also assigned ESSA Pharma an industry rank of 111 out of 265 based on the ratings given to its competitors.
A number of analysts have issued reports on EPIX shares. Bloom Burton downgraded ESSA Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, September 12th. Zacks Investment Research downgraded ESSA Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, October 3rd.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.com-unik.info/2017/12/24/essa-pharma-inc-epix-receives-consensus-rating-of-buy-from-brokerages.html.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.